- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03685916
Screening of Phytochemical Rich Ingredients as 'Functional Foods' to Improve Cardiometabolic Health (PRIFF)
February 1, 2021 updated by: JeyaKumar Henry, Clinical Nutrition Research Centre, Singapore
To find out whether consumption of different kinds of plant based functional food ingredients, traditionally used in Asia, can improve post-meal response of indicators of heart and metabolic (cardiometabolic) function.
Study Overview
Status
Completed
Conditions
Detailed Description
The study will be a non-blinded, randomised crossover trial with each participants testing between 2 to 4 different test ingredients requiring 5 or 9 separate test sessions (depending on how many the participants opt in for) on 9 non-consecutive days.
The number of test ingredients that each participant will consume will be determined by the researcher and communicated to the participant.
One of the test sessions will be a control session consisting of plain white rice (50 g available carbohydrates), with 20 g green vegetables being consumed with 200 ml of plain water.
On the other hand, the test meal ingredients will be added either to the same amount of rice during preparation or will be added to 200 ml of plain water.
The participants will be required to finish the meals within 15 minutes of serving.
Appropriate food safety guidelines will be adhered to during the preparation and administration of test meals.
We will be testing 20 separate food based traditional ingredients at either one or two doses.
20 participants will be recruited for each test food.
Assuming that a minimum 2 test ingredients are tested in each participant up to 200 Chinese male participants aged between 21 and 60 years will be recruited from the general public in Singapore with body mass index between18.5
to 25.0 kg/m2, normal blood pressure (<140/90 mmHg), and fasting blood glucose (<7.0 mmol/L).
The exclusion criteria are people who smoke, with any metabolic diseases (such as diabetes, hypertension etc), with glucose-6-phosphate dehydrogenase deficiency (G6PD deficiency), with medical conditions and/ or taking medications known to affect glycemia (glucocorticoids, thyroid hormones, thiazide diuretics), intolerances or allergies to any foods, partake in sports at the competitive and/or endurance levels and individual who intentionally restrict food intake.
Interested participants will first attend a consent and screening visit following an overnight fast to go over the informed consent procedure and ascertain their suitability to take part in the study.
During this visit, the researchers will discuss the study in more detail and go through the participant information sheet and address any queries that the potential participant may have.
If participants are willing to proceed, they will then be asked to sign the informed consent form and complete the screening visit forms and questionnaires.
If suitable to proceed, they will then undertake the screening visit measurements including height, weight, waist circumference, body impedance and blood pressure measurements.
If suitable at this stage, a finger prick blood glucose measurement will be carried out using the HemoCue® device (Helsingborg, Sweden).
The visit should last approximately 1.5 hours.
During each of the test days, participants will receive test meals in a random order made with up to 4 different food based test ingredients or the control meal (without any test ingredients).
Randomisation of test meals will be done using the =RAND() function in Excel.
The ingredients will tested in various doses and/or forms of consumption.
The participants will arrive at the study centre following an overnight fast.
After a 15 minute rest period, they will have a cannula inserted in their arm to obtain blood samples at regular intervals.
There will be 9 blood draws in total per test session: Baseline (0 h, before test meal) and 8 blood samples after test meals at 0.25 h, 0.5 h, 0.75 h, 1.0 h, 1.5 h, 2.0 h, 2.5 h and 3.0 h.
At each time point, we will collect 3 ml (about half a teaspoon) of blood.
Therefore, for each test day, up to 30 ml blood will be taken and for the entire 9 test sessions, around 270 ml of blood will be collected (around 18 tablespoons) or if the participants only opt in for 5 test sessions, they will donate approximately 150 ml of blood (around 10 tablespoons).
The blood samples collected at each timepoint will be measured for glucose, insulin and markers related to the intake of the test meal ingredients.
At 4 time points (0 h, 1 h, 2 h and 3 h), seated blood pressure measurements will also be undertaken for 3 times, using an automated sphygmomanometer (Omron, Japan) and the average of the final two blood pressure readings will be taken as that given timepoint.
Each test day should take no longer than 4 hours to complete.
Participants will be asked to refrain from alcohol and exercise the day before each test day.
The study will last between 4 and 12 weeks to compete and each test session will be undertaken on non- consecutive days, dependent on the participants' availability.
The participants will be asked to continue with their usual lifestyle during their study participation when they are not attending the test sessions.
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Singapore, Singapore, 117599
- Clinical Nutrition Research Centre
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 60 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Chinese Male
- Age between 21 to 60 years
- Body Mass Index between 18.5 to 25.0 kg/m2
- Waist circumference ≤ 90cm
- Fasting blood glucose < 7.0mmol/L
- Blood pressure <140mmHg systolic and < 90mmHg diastolic
- Do not partake in sports at the competitive and/or endurance levels and willing to stop any strenuous activity during or within 24 hours of test days
Exclusion Criteria:
- Smoking
- Allergic/intolerant to any of the test foods to be administered, or any of the following common food and ingredients: eggs, fish, milk, peanuts, and tree nuts, shellfish, soya, wheat, gluten, cereal, fruits, dairy products, meat, vegetable, sugar and sweetener, natural food colourings or flavourings, etc.
- Anyone with intentional food restrictions
- People with known glucose-6-phosphate dehydrogenase deficiency (G6PD deficiency)
- Having metabolic or cardiovascular diseases (such as diabetes, hypertension, heart condition, etc), Having any other diseases involving the small intestine or the colon (e.g., irritable bowel syndrome, inflammatory bowel disease, gastric reflux) or having any liver or kidney disorders or any family history of kidney stones.
- Having medical conditions and/or taking medications known to affect glycemia (glucocorticoids, thyroid hormones, thiazide diuretics),
- Taking any prescribed medication or dietary supplements which may interfere with the study measurements
- Excessive alcohol consumption: consuming ≥ 6 alcoholic drinks per week
- Individuals who have donated blood or taken part in other studies within 4 weeks of study participation.
- Have poor veins impeding venous access
- Have history of severe vasovagal syncope (blackouts or near faints) following blood draws
- Have known Chronic infection or known to suffer from or have previously suffered from or is a carrier of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV)
- Have active Tuberculosis (TB) or currently receiving treatment for TB
- A team member of the study or is an immediate family member (Immediate family defined as a spouse, parent, child, or sibling, whether biological or legally adopted
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Control
50 grams carbohydrate in the form of rice, 200 milliliters of plain water and 20 grams of garden peas.
|
Plain rice with plain water
|
Experimental: Cumin Rice
50 grams carbohydrate in the form of rice with cumin, 200 milliliters of plain water and 20 grams of garden peas.
|
Cumin rice with plain water
|
Experimental: Cumin Drink
50 grams carbohydrate in the form of rice, 200 milliliters of cumin extract in solution and 20 grams of garden peas.
|
Cumin drink with plain rice
|
Experimental: Cornsilk Rice (Low dose)
50 grams carbohydrate in the form of rice with cornsilk extract (low dose), 200 milliliters of plain water and 20 grams of garden peas.
|
Low dose cornsilk rice with plain water
|
Experimental: Cornsilk Rice (High dose)
50 grams carbohydrate in the form of rice with cornsilk extract (high dose), 200 milliliters of plain water and 20 grams of garden peas.
|
High dose cornsilk rice with plain water
|
Experimental: Cornsilk Drink (Low dose)
50 grams carbohydrate in the form of rice, 200 milliliters of cornsilk extract (low dose) in solution and 20 grams of garden peas.
|
Low dose cornsilk drink with plain rice
|
Experimental: Cornsilk Drink (High dose)
50 grams carbohydrate in the form of rice, 200 milliliters of cornsilk extract (high dose) in solution and 20 grams of garden peas.
|
High dose cornsilk drink with plain rice
|
Experimental: Tamarind Rice
50 grams carbohydrate in the form of rice with Tamarind, 200 milliliters of plain water and 20 grams of garden peas.
|
Tamarind rice with plain water
|
Experimental: Tamarind Drink
50 grams carbohydrate in the form of rice, 200 milliliters of Tamarind extract in solution and 20 grams of garden peas.
|
Tamarind drink with plain rice
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glucose
Time Frame: Up to 180 minutes
|
Plasma glucose measured by COBAS
|
Up to 180 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diastolic and Systolic Blood Pressure
Time Frame: Up to 180 minutes
|
Diastolic and Systolic Blood pressure measured by automated blood pressure monitor
|
Up to 180 minutes
|
Insulin
Time Frame: Up to 180 minutes
|
Plasma Insulin measured by COBAS
|
Up to 180 minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 25, 2018
Primary Completion (Actual)
September 15, 2020
Study Completion (Actual)
September 15, 2020
Study Registration Dates
First Submitted
September 25, 2018
First Submitted That Met QC Criteria
September 25, 2018
First Posted (Actual)
September 26, 2018
Study Record Updates
Last Update Posted (Actual)
February 3, 2021
Last Update Submitted That Met QC Criteria
February 1, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018/00258
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metabolic Disease
-
Yonsei UniversityUnknownCardiovascular Disease | Metabolic DiseaseKorea, Republic of
-
Clinical Nutrition Research Centre, SingaporeCompletedCardiovascular Disease | Metabolic Disease
-
San Diego State UniversityRecruitingBone Disease, MetabolicUnited States
-
Hospital Clinic of BarcelonaNovartisCompletedBone Disease, MetabolicSpain
-
The Hospital for Sick ChildrenRare Disease Foundation, Vancouver, CanadaCompleted
-
Istituto Ortopedico RizzoliCompletedOsteopenia | Bone Disease, MetabolicItaly
-
National Institutes of Health Clinical Center (CC)CompletedVascular Diseases | Cancer | Metabolic Bone Disease | Inflammatory DiseaseUnited States
-
Shenzhen Center for Chronic Disease ControlCompletedNutrition Disorders | Genetic Predisposition to Disease | Metabolic DiseaseChina
-
Istituto Ortopedico GaleazziUnknownPhysical Activity | Bone Disease, MetabolicItaly
-
Stanley Dudrick's Memorial HospitalCompletedMetabolic Bone DiseasePoland
Clinical Trials on Control
-
Claudia M. WittCompleted
-
University of California, San FranciscoWithdrawn
-
The George InstituteChanghai Hospital; University of CalgaryNot yet recruiting
-
Universidad Nacional de Educación a DistanciaMinisterio de Economía y Competitividad, SpainUnknownChronic Pain | FibromyalgiaSpain
-
University of California, Los AngelesThe National Council on Aging; City of Los Angeles Department of Aging; Los Angeles...Completed
-
Queen's University, BelfastPublic Health Agency, Health and Social Care Research and Development; Tiny...Completed
-
National Taiwan University HospitalEnrolling by invitationCognitive Function | Atrial Fibrillation, PersistentTaiwan
-
Takeshi MorimotoUniversity of the RyukyusActive, not recruitingCoronary Artery Disease | Hypertension | Type 2 Diabetes | DyslipidemiaJapan
-
Johnson & Johnson Vision Care, Inc.TerminatedRefractive Error CorrectionUnited States
-
Vanderbilt University Medical CenterCompleted